Effects of levosimendan on left atrial functions in patients with ischemic heart failure

Hamza Duygu1, Sanem Nalbantgil, Filiz Ozerkan

  • 1Department of Cardiology, Ege University Medical Faculty, Izmir, Turkey. hamzakard@yahoo.com

Clinical Cardiology
|December 17, 2008
PubMed

Insights

Levosimendan significantly improved left atrial (LA) function in patients with heart failure (HF) compared to dobutamine. This drug enhanced active emptying fraction, passive emptying fraction, and reservoir function, offering better outcomes for HF patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Physiology

Background:

  • Left ventricular (LV) dysfunction in heart failure (HF) leads to decreased left atrial (LA) contribution to LV filling.
  • LA dysfunction exacerbates reduced LV filling in HF patients.

Purpose of the Study:

  • To investigate the effects of levosimendan on LA function in patients with acute decompensated HF.
  • To compare the efficacy of levosimendan versus dobutamine in improving LA function.

Main Methods:

  • A randomized study of 60 patients with acute decompensated HF and LV ejection fraction (LVEF) < 40%.
  • Patients received either levosimendan (n=30) or dobutamine (n=30).
  • LA function parameters including active emptying fraction (AEF), passive emptying fraction (PEF), and reservoir fraction (RF) were measured before and after 24 hours of treatment.

Main Results:

  • Levosimendan significantly reduced LA volumes and improved AEF, PEF, and RF.
  • Improvements in PEF and RF were significantly greater with levosimendan compared to dobutamine.
  • Positive correlations were observed between PEF, Em, and negative correlations between PEF/AEF and E/Em in the levosimendan group.

Conclusions:

  • Levosimendan demonstrates superior efficacy in improving LA function compared to dobutamine in patients with decompensated HF.
  • The findings suggest levosimendan as a potential therapeutic option for enhancing cardiac function in HF.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.